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Serotonergic abnormalities have been reported in both autism and
epilepsy. This association may provide insights into underlying mechanisms
of these disorders because serotonin plays an important neurotrophic role
during brain development—and there is evidence for abnormal cortical
development in both autism and some forms of epilepsy. This review ex-
plores the hypothesis that an early disturbance in the serotonin system
affects cortical development and the development of thalamocortical inner-
vation, and is a potential mechanism, common to autism and pediatric
epilepsies associated with cortical dysplasia. An argument is made that
cortical malformation leads to abnormalities of thalamocortical connectiv-
ity, and that serotonin plays a critical role in this process. Finally, a role for
altered metabolism of the serotonin precursur, tryptophan, in both epilepsy
and autism is discussed. © 2004 Wiley-Liss, Inc.
MRDD Research Reviews 2004;10:112–116.
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Epilepsy is more common among autistic children than inthe general population; conversely, autism (or milderpervasive developmental disorders) is more common in
epileptic children than in the general population. There is evi-
dence for abnormalities of the neurotransmitter serotonin in
both epilepsy and autism. The role of serotonin in brain devel-
opment is briefly reviewed here and then the evidence consid-
ered for a role of an altered serotonin system in these develop-
mental disorders. We hypothesize that serotonergic
abnormalities during prenatal and early postnatal development
may lead to changes in thalamocortical connectivity, which
results in a predisposition for autism and epilepsy. In addition,
we discuss the involvement of aberrant metabolism of trypto-
phan—the metabolic precursor of serotonin—as a potential
mechanism for alterations in serotonin availability.
ALTERED PRENATAL SEROTONIN—EVIDENCE
FOR A ROLE IN AUTISM
Abnormalities of serotonergic function associated with
autism were first proposed when Schain and Freedman [1961]
reported hyperserotonemia in autistic and mentally retarded
children. This result has been replicated by several groups
[Hoshino et al., 1984; Anderson et al., 1987; Cook et al., 1990],
and extended with the recognition that blood serotonin is also
elevated in the first degree relatives of these children [Leventhal
et al., 1990; Piven et al., 1999; Cook et al., 1994; Leboyer et al.,
1999]. How the abnormalities of blood serotonin might be
related to brain serotonin, however, is not well understood.
Several recent studies have reported associations of gene
dysfunction that may impact serotonin metabolism in autism.
For example, our group has found a susceptibility mutation in a
promoter variant of the tryptophan 2,3-dioxygenase gene [Nabi
et al., 2004]. Tryptophan 2,3-dioxygenase is a rate-limiting
enzyme in the metabolism of tryptophan by the kynurenine
pathway. A mutation that results in decreased activity of this
enzyme could decrease the metabolism of tryptophan through
the kynurenine pathway, causing a shift toward increased levels
of serotonin. Interestingly, tryptophan 2,3-dioxygenase, as well
as indoleamine 2,3-dioxygenase (which also catalyses tryptophan
metabolism by the kynurenine pathway), are expressed in the
placenta and have a role in the prevention of allogeneic rejection
of the fetus [Munn et al., 1998; Suzuki et al., 2001].
Another recent study investigated the relationship of ma-
ternal genotypes for monoamine oxidase-A (MAO-A), an en-
zyme that metabolizes serotonin, with the susceptibility of au-
tism in their offspring. Jones et al. [2004] reported that maternal
genotypes containing specific polymorphisms at the MAO-A
locus showed significant negative correlations with the intelli-
gence quotient (IQ) in children with autism. These results are
consistent with those of Cohen et al. [2003], who found that a
low-activity MAO-A allele (due to an upstream variable-num-
ber tandem repeat region) is associated with both lower IQ and
more severe autistic behavior in children, as compared to the
high-activity allele.
In addition, the serotonin transporter is highly expressed
in the brush border membrane of the human placenta and may
mediate transport of serotonin from the maternal circulation to
the developing fetus [Balkovetz et al., 1989]. Efforts to relate
increased blood serotonin to polymorphisms of the serotonin
transporter have been largely unsuccessful, although a small
effect on blood serotonin has not been ruled out [Persico et al.,
2000; Anderson et al., 2002; Persico et al., 2002; Betancur et al.,
2002]. Given that there is expression of the serotonin transporter
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in the placenta, a maternal modifier effect
of the serotonin transporter might con-
stitute a risk factor for autism.
These observations have led to the
view that alterations of serotonin (or
tryptophan) metabolism and/or transport
during prenatal development may regu-
late key steps during cortical develop-
ment. Such a view is supported by recent
evidence showing that abnormal seroto-
nin levels in the brain may alter prenatal
cortical development. Rakic and col-
leagues have demonstrated that seroto-
nergic fibers innervate Cajal Retzius
cells, which are necessary for cortical col-
umn development [Janusonis et al.,
2004]. Furthermore, these investigators
showed that treatment with the serotonin
agonist 5-methoxytryptamine during fe-
tal development led to alterations in brain
reelin levels (a glycoprotein produced by
Cajal Retzius cells) and abnormalities of
presubicular cortical column develop-
ment. These results are extremely pro-
vocative because both abnormal levels of
reelin [Fatemi et al., 2001] and abnor-
malities in cortical columns [Casanova et
al., 2002a, 2002b] have been demon-
strated in human autism autopsy brain
tissue. In particular, Casanova et al.
[2002a, 2002b] reported that there was
an increased number of minicolumns,
combined with fewer cells per column or
greater cell dispersion, in autism brain




To determine whether there are
serotonergic abnormalities in the brains
of children with autism, we have evalu-
ated serotonin synthesis capacity in vivo
with positron emission tomography
(PET), using the tryptophan analog
alpha[11C]methyl-L-tryptophan (AMT)
as a tracer. AMT, developed as a PET
tracer for serotonin synthesis [Diksic et
al., 1991; Muzik et al., 1997; Chugani et
al., 1998a], is an analog of tryptophan,
the precursor for serotonin. We have ex-
amined this tracer in a study of autistic
and nonautistic children. Our studies il-
lustrated two fundamentally different
types of serotonergic abnormalities in au-
tistic children [Chugani et al., 1997,
1999]. The first is a difference in the
change with age in whole brain serotonin
synthesis. Global brain values for seroto-
nin synthesis capacity were obtained for
30 healthy seizure-free autistic children,
for 8 of their healthy nonautistic siblings,
and for 16 epileptic children without au-
tism. For nonautistic children (with or
without epilepsy), serotonin synthesis ca-
pacity was 200% of adult values until
the age of 5 years and then declined
toward adult values. In autistic children,
serotonin synthesis capacity increased
gradually between the ages of 2 years and
15 years to values 1.5 times the adult
normal values. In other words, at a given
early age less than 5 years, the serotonin
synthesis capacity in an autistic child is
much lower than that in a nonautistic
child. These data suggest that in human
brain, there is a period of high brain
serotonin synthesis capacity during early
childhood and that this developmental
process is disrupted in autistic children.
The second type of abnormality
relates to focal abnormalities in brain se-
rotonin synthesis. Asymmetries of AMT
uptake in frontal cortex, thalamus, and
cerebellum were visualized in a small
sample of children with autism [Chugani
et al., 1997]. In a larger group of autistic
children, we have shown that subgroups
of autistic children can be defined by
presence or absence, and side of cortical
asymmetry, in AMT abnormalities; these
subgroups differed on measures of lan-
guage and handedness. Autistic children
with left cortical AMT decreases showed
a higher prevalence of severe language
impairment, whereas those with right
cortical decreases showed a higher prev-
alence of left- and mixed-handedness
(Chandana et al., in press).
In the normal human brain, there
are significant differences in minicolumn
organization between the left and right
sides [for review, see Hutsler and Ga-
luske, 2003]. These differences suggest
that alterations in minicolumn organiza-
tion—in autism—may have a profound
impact on hemispheric specialization and
functions that dependent on hemispheric
specialization (such as language). In nor-
mal brain, the width of minicolumns and
the distance between the columns is
larger on the left than on the right [Sel-
don, 1981a, 1981b, 1982; Buxhoeveden
et al., 2001]. Seldon [1981a, 1981b,
1982] also showed that pyramidal cells in
the posterior language cortex on the left
contacted fewer columnar units than on
the right. In addition, there is asymmetry
in the size of the pyramidal cells consti-
tuting the minicolumns, with a greater
number of large pyramidal cells in the left
hemisphere than in the right hemisphere
[Hutsler, 2003]. As a consequence of
these differences, pyramidal cells in the
left hemisphere contact fewer adjacent
minicolumns than pyramidal cells in the
right hemisphere. Conversely, macrocol-
umns appear not to be asymmetric in
size, although the distance between mac-
rocolumns has been reported to be 20%
greater on left than on the right in Brod-
mann area 22 [Galuske et al., 2000].
The serotonin transporter is tran-
siently expressed by glutamatergic
thalamocortical afferents [D’Amato et al.,
1987; Bennett-Clarke et al., 1996; Leb-
rand et al., 1996] during the first 2 post-
natal weeks in rodents. Postnatal seroto-
nin levels regulate the size of cortical
barrel macrocolumns: too little serotonin
leads to smaller barrel macrocolumns and
too much serotonin leads to larger bar-
rels. Depletion of serotonin during the
postnatal period delays the development
of the barrel fields of the rat somatosen-
sory cortex [Blue et al., 1991; Osterheld-
Haas et al., 1994] and decreases the size
of the barrel fields [Bennett-Clarke et al.,
1994]. In contrast, increased serotonin
brain levels during this critical period, as
in the MAO-A knockout mouse or se-
rotonin transporter knockout mouse
[Salichon et al., 2001], results in increased
tangential arborization of thalamocortical
axons, resulting in blurring of the bound-
aries of the cortical barrels [Cases et al.,
1996]. We propose that the presence of
smaller, more closely spaced minicol-
umns in the brains of autistic children
[Casanova et al., 2002a, 2002b] might
trigger compensatory changes in cortical
serotonin synthesis in the early postnatal
period when serotonin regulates forma-
tion of thalamocortical afferents. For ex-
ample, decreased serotonin might nor-
malize the number of minicolumns per
macrocolumn innervated by a given set
of thalamocortical afferents by decreasing
thalamocortical axon arborization.
EVIDENCE FOR ROLE OF
SEROTONIN IN EPILEPSY
Although in adults the predomi-
nant form of epilepsy involves medial
temporal lobe structures, epilepsy in
young children is most commonly asso-
ciated with focal or diffuse cortical mal-
formations [Kuzniecky and Barkovich,
2001]. There are many lines of evidence
implicating serotonergic mechanisms as
playing a role in epileptogenesis in both
humans and animals [reviewed in Toczek
et al., 2003; Teskey et al., 2004]. In hu-
man brain tissue surgically removed for
seizure control, levels of 5-HIAA (5-hy-
droxyindole acetic acid, the breakdown
product of serotonin) were found to be
higher in actively spiking temporal cor-
tex, as compared to normal controls
[Louw et al., 1989; Pintor et al., 1990].
Increased serotonin immunoreactivity
has also been reported in human epileptic
brain tissue resected for the control of
epilepsy [Trottier et al., 1996]. Interest-
ingly, the increase in serotonin immuno-
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reactivity was seen in “fine, wispy fibers”
characteristic of the pattern of staining of
thalamocortical fibers expressing seroto-
nin transporters during development,
rather than the “beads on a string” stain-
ing typical of raphe-cortical serotonergic
fibers. In a study that compared epilepsy
patients with cortical dysplasia with pa-
tients showing normal imaging charac-
teristics, Fedi et al. [2001] reported in-
creased AMT uptake in 60% of the
patients with cortical dysplasia but only
30% of patients with normal MRIs. Ju-
hasz et al. [2003] demonstrated that ob-
jectively identified cortical areas of in-
creased AMT uptake (PET studies) were
highly specific for the lobe of seizure
onset, both in patients with normal MRI
and in those with developmental cortical
malformations. Interestingly, the spatial
comparison of AMT PET abnormalities
with intracranial EEG recordings dem-
onstrated that cortex adjacent to the re-
gion showing increased AMT uptake is
most often the site of seizure onset, al-
though parts of the region with increased
AMT uptake itself were also commonly
epileptogenic.
This epileptogenic pattern is simi-
lar to that reported for the microgyrus
lesion model in the rat, in which focal
cortical lesions are produced by freezing a
small cortical region on postnatal day 0 or
1 [Dvorak and Feit, 1977]. Dvorak and
Feit [1977] showed that a freeze lesion in
the neonatal period kills most of the neu-
rons present at the time of the lesion. For
a lesion on postnatal day 1, neurons in
cortical layers IV and V are destroyed
resulting in a four-layer cortex. For le-
sions on postnatal day 0, layer IV neurons
are spared leading to less retargeting of
thalamocortical afferents [Jacobs et al.,
1999]. Microelectrode recordings show
that epileptiform activity arises from the
adjacent normal appearing cortex, and this
epileptiform activity is sustained even if it
is surgically separated from the focal le-
sion [Jacobs et al., 1999]. This finding has
led to the hypothesis that the epilepti-
form activity results from reorganization
of afferent inputs, where adjacent normal
cortex is hyperinnervated due to lack of
appropriate target neurons in the lesion.
Indeed, Rosen et al. [2000] have shown
that cortical lesions result not only in
increased thalamic innervation of cortex
adjacent to the microgyrus caused by
freeze lesion in the neonatal period, but
also in changes in corticothalamic and
callosal efferents to homotopic cortical
regions from the perilesional region.
As discussed above, thalamocorti-
cal afferent fibers contain serotonin dur-
ing development due to transient expres-
sion of the serotonin transporter
[Bennett-Clarke et al., 1996; Lebrand et
al., 1996]. We hypothesize that these fi-
bers continue to express the transporter
in tissue with cortical dysplasia rather
than down-regulating the serotonin
transporter with brain development.
Such a developmental abnormality
would be consistent with the report of
increased immunoreactivity of fine fibers
(presumably thalamocortical) by Trottier
et al., [1996] in the epileptic cortex.
These fibers tend to concentrate at the
edge of cortical dysplasias, perhaps due to
lack of proper targets within the dysplas-
tic tissue.
Teskey et al. [2004] have recently
reported that MAO-A knockout mice
are more susceptible than wild-type mice
to seizures induced by electrical and pen-
tylenetetrazol kindling. As discussed
above, thalamocortical innervation of the
cortex is profoundly affected in the
MAO-A knockout mouse. MAO
knockout mice show shorter latency to
the onset of the first seizure, but shorter
total duration of seizures and fewer sei-
zures per day. Thus, these authors con-
clude that the MAO-A knockout mice
have a lower seizure threshold, but a
relative resistance to epileptogenesis.
They hypothesized that the shorter la-
tency to the first seizure is due to changes
in brain organization, a consequence of
elevated serotonin during development;
the resistance to epileptogenesis is attrib-
uted to the persistent high levels of sero-
tonin in the adult animals.
Increased serotonin synthesis, as
evidenced by increased AMT uptake ad-
jacent to the seizure focus, might also be
related to sprouting of raphe-cortical se-
rotonergic fibers due to release of brain-
derived neurotrophic factor (BDNF)
from the active epileptic focus. BDNF
mRNA and protein are increased in the
seizure focus following seizures in epi-
lepsy patients as well as in a number of
epilepsy animal models [for review, see
Binder et al., 2001]. Infusion of BDNF
into rat brain increases sprouting of sero-
tonergic fibers [Mamounas et al., 2000],
suggesting that the increased AMT up-
take adjacent to the focus may be the
result of serotonergic fiber sprouting in-
duced by BDNF. Support for this type of
mechanism has been obtained in studies
of adult temporal lobe epilepsy (TLE).
Natsume et al. [2003] reported increased
AMT uptake in the hippocampus ipsilat-
eral to the focus of TLE patients with
normal hippocampal volumes but not in
patients with hippocampal atrophy.
These data may be relevant to seizure-
induced neurogenesis [Parent, 2002] be-
cause there is evidence that serotonin is a
regulator of neurogenesis in the dentate
gyrus [Gould, 1999]. Speculatively, in-
creased neurogenesis in the patients
showing increased AMT uptake in hip-
pocampus may account for the normal
hippocampal volume in these patients.
Increased uptake of AMT in epi-
lepsy patients may also reflect tryptophan
metabolism via the kynurenine pathway
in the brain. Under normal circum-
stances, the concentration of tryptophan
metabolites of this pathway are between
100- and 1000-fold lower than the con-
centration of tryptophan in the brain
[Saito et al., 1993]. In comparison, the
sum of the concentrations of serotonin
and its metabolite 5-HIAA is approxi-
mately one-fifth the concentration of
tryptophan in brain [Hery et al., 1977].
Therefore, the kynurenine pathways are
not expected to contribute significantly
to the accumulation of AMT in brain
under normal circumstances. However,
following brain injury or immune activa-
tion, there is induction of indoleamine
2,3-dioxygenase [Saito et al., 1993], lead-
ing to a significant increase of kynurenine
pathway metabolites. Several metabolites
of the kynurenine pathway—quinolinic
acid, kynurenine, and 3-hydroxykynure-
nine—are convulsants through their action
as agonists at N-methyl-D-aspartate
(NMDA) receptors [Perkins and Stone,
1982, 1983; Vezzani et al., 1985; Lapin,
1978, 1980, 1982]. Kynurenic acid,
however, which is another metabolite in
this pathway and is an NMDA antagonist
[Perkins and Stone, 1982], has been re-
ported to suppress epileptiform activity in
animal models of epilepsy [Sharfman and
Ofer, 1997]. It has been postulated that
metabolites of the kynurenine pathway
might play a role in the initiation and
maintenance of seizures in human seizure
disorders [Feldblum et al., 1988; Heyes et
al., 1990]. Quinolinic acid concentra-
tions are apparently not increased in the
seizure focus as compared to nonfocus
brain regions from adults undergoing
surgery for temporal lobe epilepsy [Heyes
et al., 1990]. However, we have demon-
strated in patients with tuberous sclerosis
5-fold higher concentrations of quino-
linic acid in tubers that also show ele-
vated AMT accumulation (i.e., epilepto-
genic tubers) compared to tubers and
brain tissue that show no elevated AMT
accumulation [Chugani et al., 1998b].
These findings suggest that, in at least
some cases, the mechanism of epilepto-
genesis may involve activation of the
kynurenine pathway, leading to the pro-
duction of endogenous convulsants. Fur-
thermore, induction of this pathway may
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also result in altered availability of tryp-
tophan for serotonin synthesis.
CONCLUSION
We have reviewed a number of
studies that indicate that serotonergic ab-
normalities are associated with abnormal-
ities of cortical development and
thalamocortical connectivity and propose
that these serotonin-linked abnormalities
are common mechanistic features of au-
tism and epilepsy. Abnormal serotonin
transport or synthesis during brain devel-
opment may directly affect formation of
intracortical and thalamocortical cir-
cuitry. The relative balance of trypto-
phan metabolism, regulated by the sero-
tonin and kynurenine pathways, may also
be important in both disorders. These
serotonergic abnormalities may at least
partially explain why autism and epilepsy
are commonly associated. f
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